

JUBILANT PHARMA LIMITED
(Company Registration No. 200506887H)
(Incorporated in the Republic of Singapore)
Registered office: 80 Robinson Road, #02-00, Singapore 068898

August 25, 2021

Singapore Exchange Securities Trading Limited
11 North Buona Vista Drive #06-07
The Metropolis Tower 2
Singapore 138589

Dear Sir / Madam,

Subject: Announcement

We enclose a communication pertaining the Company's US\$200,000,000 6.00% Senior Notes due 2024.

This is for your kind information and records.

Thanking you,

Yours faithfully,
For Jubilant Pharma Limited

Sd/-
Shyam S. Bhartia
Chairman and Managing Director

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OR IN ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE PROHIBITED BY APPLICABLE LAW.

This announcement is not a solicitation of consents with respect to the Notes. The Consent Solicitation is being made solely pursuant to the Consent Solicitation Statement and related documents which set forth the complete terms of the Consent Solicitation.

This announcement and any materials relating to the Consent Solicitation do not constitute, and may not be used in connection with, any form of offer or solicitation in any place where such offers or solicitations are not permitted by law.

Capitalized terms used and not otherwise defined in this announcement have the meanings given to them in the Consent Solicitation Statement.

THIS DOCUMENT IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION. IF YOU ARE IN DOUBT ABOUT THE ACTION YOU SHOULD TAKE, YOU SHOULD CONSULT IMMEDIATELY YOUR STOCKBROKER, BANK MANAGER, SOLICITOR, ACCOUNTANT OR APPROPRIATELY AUTHORIZED INDEPENDENT FINANCIAL ADVISER.



**Jubilant Pharma Limited announces receipt of requisite consents
and expiration of Consent Solicitation**

SINGAPORE, August 25, 2021 – Jubilant Pharma Limited (the “**Company**”) hereby announces that, as reported by the Information and Tabulation Agent, the requisite holders of the Issuer’s U.S.\$200,000,000 6.00% Senior Notes due 2024 (ISIN: XS1958658509, Common Code: 195865850) (the “**Notes**”) have consented to the Proposed Waiver in relation to the indenture governing the Notes, upon the terms and subject to the conditions set forth in the Consent Solicitation Statement dated August 16, 2021 (the “**Consent Solicitation Statement**”).

As of 5.00pm, Central European Summer Time, on August 24, 2021 (the “**Expiration Deadline**”), the Company received valid Consents from holders representing approximately 63.93% of the aggregate principal amount of the Notes outstanding.

Subject to the terms and conditions set forth in the Consent Solicitation Statement, the Issuer will pay holders who validly delivered their Consents on or prior to the Expiration Deadline the Consent Fee of US\$2 per US\$1,000 principal amount of the Notes consented.

It is anticipated that payment of the Consent Fee to holders of Notes who have delivered Consents pursuant to the Consent Solicitation at or prior to the Expiration Deadline will occur on August 26, 2021 (the “**Settlement Date**”). Consideration is payable only if all conditions to the Consent Solicitation are satisfied or waived prior to the Settlement Date, in the Company’s sole discretion.

The solicitation agents for the Consent Solicitation (the “**Solicitation Agents**”) are DBS Bank Ltd., J.P. Morgan Securities plc and UBS AG Singapore Branch (UEN S98FC5560C)¹. The information and tabulation agent for the Consent Solicitation is Morrow Sodali Limited (the “**Information and**

¹ UBS AG is incorporated in Switzerland with limited liability.

Tabulation Agent”). All documentation relating to the Consent Solicitation, together with any updates, can be found at <https://bonds.morrowsodali.com/jubilantpharma>. Questions about the terms of the Consent Solicitation should be directed to the Solicitation Agents at the e-mail addresses, telephone numbers and addresses listed below.

Solicitation Agents

DBS Bank Ltd.

12 Marina Boulevard, Level 42
Marina Bay Financial Centre Tower 3
Singapore 018982
Fax: +65 6225 6783
Email: liabilitymanagement@dbs.com

J.P. Morgan Securities plc

25 Bank Street, Canary Wharf
London E14 5JP
United Kingdom
Fax: +44 (0)20 3493 0682
Email: liability_management_asia@jpmorgan.com

UBS AG Singapore Branch

9 Penang Road
Singapore 238459
Phone: +65 6495 8623
Email: OL-LiabilityManagement-SEA@ubs.com

The Information and Tabulation Agent for this Consent Solicitation is:

Information and Tabulation Agent.

Morrow Sodali Limited

Email: JubilantPharma@investor.morrowsodali.com

Consent Website: <https://bonds.morrowsodali.com/jubilantpharma>

In London:

103 Wigmore Street
W1U 1QS
London
Telephone: +44 20 4513 6933

In Hong Kong:

Unit 23-106, LKF Tower
33 Wyndham Street, Central
Hong Kong
Telephone: +852 2319 4130

DISCLAIMER

Holders must read this announcement in conjunction with the Consent Solicitation Statement. This announcement and the Consent Solicitation Statement contain important information which should be read carefully before any decision is made with respect to the Proposed Waiver in respect of the Notes.

None of the Solicitation Agents, the Trustee or the Information and Tabulation Agent expresses any view as to the merits of the Proposed Waiver. None of the Solicitation Agents, the Trustee or the Information and Tabulation Agent has been involved in negotiating the Proposed Waiver or makes any representation that all relevant information has been disclosed to the Holders in or pursuant to this announcement or the Consent Solicitation Statement. Furthermore, none of the Solicitation Agents, the Trustee or the Information and Tabulation Agent makes any assessment of the impact of the Proposed Waiver on the interests of the Holders or makes any recommendations on the Consent Solicitation relating to the Notes or whether they should consent to the Proposed Waiver. Accordingly, Holders should seek their own financial, legal and tax advice.

Holders whose Notes are held on their behalf by a broker, dealer, commercial bank, custodian, trust company or accountholder must contact and request such broker, dealer, commercial bank, custodian, trust company or accountholder if it wishes to participate in the Consent Solicitation. The distribution of this announcement and the Consent Solicitation Statement in certain jurisdictions may be restricted by law. Persons into whose possession this announcement or the Consent Solicitation Statement comes are required by the Company, the Trustee, the Solicitation Agents and the Information and Tabulation Agent to inform themselves about, and to observe, any such restrictions. This announcement and any materials relating to the Consent Solicitation do not constitute, and may not be used in connection with, any form of offer or solicitation in any place where such offers or solicitations are not permitted by law.

If a jurisdiction requires that the Consent Solicitation be made by a licensed broker or dealer and the Solicitation Agents, or their affiliates, is such a licensed broker or dealer in that jurisdiction, the Consent Solicitation shall be deemed to be made by such Solicitation Agent or affiliate, as the case may be, on behalf of the Company in such jurisdiction where it is so licensed and the Consent Solicitation are not being made in any such jurisdiction where the Solicitation Agents or any one of their affiliates are not so licensed.